07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Integrin-linked kinase (ILK); parvin-b (PARVB) Mouse and cell culture studies suggest inhibiting ILK and PARVB signaling...
08:00 , Feb 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Insulin-like growth factor binding protein 2 (IGFBP2); integrin a5 (CD49e); integrin b1 (CD29); integrin-linked kinase (ILK);...
08:00 , Jan 23, 2012 |  BioCentury  |  Emerging Company Profile

Dermira: Success is skin deep

Founded by a management team with a history of growing and selling dermatology assets, Dermira Inc. has set off down a similar path with four molecules that originated at QLT Inc. CEO Thomas Wiggans and CMO...
07:00 , Aug 25, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Integrin-linked kinase (ILK) In vitro and mouse studies suggest a propanamide derivative could help treat...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

Great(er) expectations

Bankers and buysiders are adamant that despite a difficult fourth quarter - and in part because of it - they have positive expectations for 2010. Their views are based on factors including the wrapping up...
07:00 , Jun 5, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Neurology ...
07:00 , Jun 21, 2004 |  BioCentury  |  Strategy

Not just skin deep

Not just skin deep Product Indication Status Company Partner Visudyne Age-related macular degeneration (AMD) Mkt QLT Novartis Eligard leuprolide 1-, 3- and 4-month depot Prostate cancer Mkt ATRX Sanofi-Synthelabo (U.S.); MediGene/Yamanouchi(Europe); Sosei/Nippon(Japan) Eligard...
07:00 , Apr 10, 2000 |  BioCentury  |  Politics, Policy & Law

Too much Congress is bad for your health

Too much Congress is bad for your health The FDA has been dragooned into withdrawing most of its proposed rule to regulate ephedra, a dietary supplement, adding to the sorry list of public health setbacks...
08:00 , Mar 20, 2000 |  BC Week In Review  |  Company News

Kinetek other research news

Kinetek researchers and colleagues published in the Proceedings of the National Academy of Sciences that ILK activity is elevated in cells containing mutations in PTEN, a tumor suppressor gene, and that inhibition of ILK...
08:00 , Mar 13, 2000 |  BC Extra  |  Clinical News

Kinetek publishes potential cancer treatment

Kinetek (Vancouver, B.C.) published in the Proceedings of the National Academy of Sciences that Integrin-linked kinase (ILK) activity is elevated in cells containing mutations in PTEN, a tumor suppressor gene, and that inhibition of...